Figure 3.
The combination of targeted therapies with tepotinib or TNO155 decreases MAPK/PI3K downstream signaling more potently than either of the agents alone
(A) HCC827 tetON-MET and NCI-H358 tetON-MET, as well as (B) NCI-H1781 tetON-MET and KM12 tetON-MET cells were induced with doxycycline for 48 h before they were treated with the respective inhibitors and combinations for 6 h. Western blot analysis was performed with the indicated antibodies.
